Subscribe to Newsletter

Paul-Peter Tak

President and CEO, Candel Therapeutics

Tak is ranked at 150 in the 2022 world ranking of top 1,000 scientists in immunology and was elected Fellow of the Academy of Medical Sciences, UK. He has served as Senior Vice President, Chief Immunology Officer, and Global Development Lead at GSK, where he oversaw the creation of a portfolio of new medicines. He then cofounded Sitryx Therapeutics and led Tempero Pharmaceuticals (acquired by GSK) and Kintai Therapeutics (merged with Senda Biosciences) as CEO.

At Candel Therapeutics, he brought together a world-class executive team, prioritized the portfolio, initiated the new enLIGHTENTM Discovery Platform, created a high-profile Research Advisory Board, and led the company to an IPO on the NASDAQ. Candel has recently presented proof of concept for its viral immunotherapies across multiple solid tumors.  

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine